BBIO: Encaleret Phase 3 CALIBRATE trial results in ADH1
BBIO says its Encaleret increased bone turnover and improved participant-reported symptoms in the Phase 3 CALIBRATE trial in ADH1.
Story updates
03:48:09 PM UTC
SquawkNews
Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1- 100% of participants who received encaleret reported improvements in at least one ADH1 symptom compared to 46% of participants who received standard of care- Improvemen…